| Similar Articles |
|---|
 |
The Motley Fool
May 5, 2005
Stephen D. Simpson |
Will Anybody Love Angiotech? Despite the success of the Boston Scientific Taxus stent, Angiotech's stock is trading at low levels.   |
The Motley Fool
January 28, 2005
Stephen D. Simpson |
SurModics Stays in the Hot Spot Medical technology coatings specialist occupies the hazy world between biotech and medical devices. Though priced roughly in line with peers like Flamel or Nektar, the stock trades at almost 10 times sales and even the forward P/E is a robust 26.5. |
The Motley Fool
March 8, 2005
Stephen D. Simpson |
The Stent Wars Continue Although Boston Scientific and Johnson & Johnson have been beating each other silly for market share, recent clinical data suggest little functional difference between drug-coated stents. |
The Motley Fool
May 25, 2005
Stephen D. Simpson |
Stent Wars 2: The Market-Share Menace The battle for drug-coated stent market share between Johnson & Johnson and Boston Scientific may not be as exciting as watching Obi-Wan Kenobi and Anakin Skywalker fight, but the outcome matters for investors. |
The Motley Fool
July 26, 2004
W.D. Crotty |
Boston Scientific on the Rebound The medical device maker posts robust earnings, softening the blow of the stent delivery system recall. |
The Motley Fool
February 1, 2005
Stephen D. Simpson |
Stent Maker's Hearty Returns Medical device company Boston Scientific rebounds from cardiac stent recall with strong growth. |
The Motley Fool
July 19, 2004
W.D. Crotty |
Gold Mine Cave-In? Will recalls involving the Taxus stent mar the future earnings of Boston Scientific? |
The Motley Fool
April 13, 2004
Alyce Lomax |
J&J Makes the Day It may be over a hundred years old, but the company reports a spry first quarter. |
The Motley Fool
July 13, 2004
Jeff Hwang |
J&J Weathers Stent Duel The medical device and diagnostics business Johnson & Johnson delivers a solid second quarter despite competition from Boston Scientific's Taxus stent. |
The Motley Fool
February 24, 2004
Alyce Lomax |
J&J, Guidant Join Forces With intense rivalry looming, is a competitive partnership in vain? |
The Motley Fool
November 22, 2006
Brian Lawler |
Dueling Fools: Johnson & Johnson Bear J&J's dividend does provide investors with some degree of income, but a CD does, too -- without a health-care stock's risks. |
The Motley Fool
October 12, 2004
Alyce Lomax |
Take It Away, J&J Should investors sweat a coming slowdown in growth for pharmaceutical and consumer products giant Johnson & Johnson? |
BusinessWeek
April 17, 2006
Amy Barrett |
Unclogging J&J's Pipeline Maker of coronary stents Johnson & Johnson needs to release more products and grab back its lead in the crowded market it created. |
The Motley Fool
October 12, 2007
Billy Fisher |
Dueling Fools: Johnson & Johnson Bear The bearish opinion on J&J is that it is an impressive company that may have its best days behind it. |
The Motley Fool
January 20, 2004
Alyce Lomax |
Is J&J Pain-Free? Fourth-quarter revenues surge, but rivals are waiting in the wings. |
BusinessWeek
August 8, 2005
Amy Barrett |
BW 50: In A Bind Over Stents Safety concerns about drug-coated stents from Johnson & Johnson and Boston Scientific could open the way for rivals. |
The Motley Fool
April 30, 2008
Brian Lawler |
Additional Aggravation for Angiotech Could any drugmaker have a worse start to the year? |
The Motley Fool
July 19, 2005
Stephen D. Simpson |
Waiting for Boston Scientific's Second Act The market for drug-coated stents is still lucrative, but BSX needs to deliver on its R&D efforts for long-term success. Investors, take note. |
The Motley Fool
July 30, 2004
W.D. Crotty |
This Nanotech Deserves Respect While the stock recently hit some potholes, Flamel still looks good for the future. |
The Motley Fool
October 14, 2005
Stephen D. Simpson |
Boston's Stunts With Stents Tough domestic stent competition is weighing on results from one-trick pony Boston Scientific. The company is in a transitional period and that's at least part of why the stock is down where it is. |
BusinessWeek
September 22, 2003
Faith Arner |
When Will This Stent See Circulation? Boston Scientific must clear the FDA, among other hurdles. |
The Motley Fool
November 7, 2007
Billy Fisher |
SurModics Serves Up a Big Quarter The drug delivery technology company reports record revenue and operating cash flow in its fiscal fourth quarter. |
The Motley Fool
June 22, 2005
Stephen D. Simpson |
Stent Wars: Jury Strikes Back A jury finds that Boston Scientific has violated J&J's stent patents, but the battle is only beginning. Meanwhile, Boston Scientific continues to have market-share leadership in drug-coated stents and makes quite a bit of money from it. |
The Motley Fool
May 17, 2006
Stephen D. Simpson |
Angiotech Pharmaceuticals: Rebuilding or Reloading? This small Canadian drug-delivery outfit is reshaping and diversifying. Investors, is it time to buy? |
BusinessWeek
September 6, 2004
Mara Der Hovanesian |
Ready to Rebound at Angiotech Boston Scientific's July 2 recall of its drug-coated stents has sent shares tumbling 17%. Some analysts call it a buying opportunity. And, they say, little-known Angiotech Pharmaceuticals, a specialty outfit in Vancouver, may be an even better bet. |
The Motley Fool
May 28, 2004
W.D. Crotty |
Boston Scientific's Stent Gold Mine The company is starting two or more years of high profitability. |
The Motley Fool
November 2, 2006
Brian Lawler |
Angiotech's Study Troubles The results of recent studies in medical journals have brought the company's forecasts down. Investors, take note. |
